14 minutes agoThe FDA sanctioned trial for remestemce-L is very intensive and incredibly detailed.
https://www.clinicaltrials.gov/ct2/show/NCT04371393?term=remestemcel-L&cond=COVID-19&draw=2&rank=3ThePrimary outcomes measure is: "Number of all-cause mortality within 30 days of randomization".The secondary outcomes measures are:There are 35 secondary data points, too many to list here. The message here is: Mesoblast is being very thorough with their trial and they are covering all the bases. They seriously intend to get this approved by the FDA on the first shot, without questions or doubts...
Glta
LongStock14 minutes agoThe FDA sanctioned trial for remestemce-L...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.030(2.73%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.21 | $1.05 | $28.73M | 25.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 14264 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 24626 | 3 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
-0.030 ( 2.52 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.21 | $1.05 | 5190842 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| MSB (ASX) Chart |